VRCA stock gains 12.23% as Needham holds its view

VRCA stock rose 12.23% to $5.69 on August 28, 2026, while a fresh analyst note kept a Hold rating and a $13.67 average target in view.

Verrica Pharmaceuticals Inc. (US92511P1021) stock rose 12.23% to $5.69 on August 28, 2026, with the move lifting the company's market value to $97.06 million. A fresh note kept a Hold stance in place while the Street average target stood at $13.67.

Analyst view and valuation

The latest analyst note from a market-news report said Needham maintained a Hold rating, while the same item cited a Strong Buy consensus and a $13.67 average price target. Against a $5.69 closing price, that target implies the shares still trade well below the level analysts collectively point to.

Revenue and loss

The latest company snapshot puts Q2 FY26 revenue at $5.86 million and EPS at -$0.48, with earnings per share missing the estimate by 1 cent. The same source shows TTM EPS of -1.74 and profit margin of -224.38%, a reminder that valuation still sits beside a wide loss profile.

That gap matters because the stock's 12.23% one-day move arrived with a market cap of $97.06 million, not with a fresh commercial breakout or a rerating from profitability. Investors are instead weighing a low absolute share price against a business that is still reporting quarterly losses.

Product focus

Verrica's lead product is YCANTH, the company's topical treatment for molluscum contagiosum. It remains the clearest product-level reference point for the business as the market follows revenue, losses and analyst sentiment.

Shares and session

VRCA closed at $5.69 on August 28, 2026, after a 12.23% gain, and the session marked a move from the prior close of $5.07 by $0.62. The stock's market capitalization stood at $97.06 million in the same snapshot.

Fact box

Company: Verrica Pharmaceuticals Inc.
ISIN: US92511P1021
Ticker: VRCA
Exchange: Nasdaq
Price (as of August 28, 2026, 4:00 p.m. ET): $5.69 USD
Market cap: $97.06 million (as of August 29, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Russell 3000